Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
|Podcasts|October 8, 2020
The Cutaneous Connection: Episode 8- Building Your Brand as a Physician
Author(s)Morgan Petronelli
Media expert Paige Velasquez Budde, CEO of Zilker Media, explains the importance of building a brand as a physician, as well as some mistakes to avoid and tips on how to grow and shape your brand.
Advertisement
Advertisement
Related to this article
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
This review of the latest dermatological studies includes insights on stem cell therapies for skin rejuvenation, smoke exposure in HS, hair loss in pediatric IBD, and more.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.
Victoria Werth, MD, professor of dermatology and rheumatology at the University of Pennsylvania, recently discussed brepocitinib's FDA approval for dermatomyositis and what the VALOR trial data mean for patients and clinicians.
Advertisement
Advertisement
Trending on Dermatology Times
1
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
2
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
3
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
4
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
5